Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma
Agonistic CD40 antibodies (αCD40) have broad immunostimulatory properties, however their efficacy in glioma remains unclear. Here the authors show that αCD40 promotes the formation of tertiary lymphoid structures but does not improve survival and impairs the response to immune checkpoint blockade in...
| Main Authors: | , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Nature Publishing Group
2021-07-01
|
| Series: | Nature Communications |
| Online Access: | https://doi.org/10.1038/s41467-021-24347-7 |
| id |
doaj-960c23767579410eb75556847b8c9b3f |
|---|---|
| record_format |
Article |
| spelling |
doaj-960c23767579410eb75556847b8c9b3f2021-07-11T11:42:49ZengNature Publishing GroupNature Communications2041-17232021-07-0112111410.1038/s41467-021-24347-7Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in gliomaLuuk van Hooren0Alessandra Vaccaro1Mohanraj Ramachandran2Konstantinos Vazaios3Sylwia Libard4Tiarne van de Walle5Maria Georganaki6Hua Huang7Ilkka Pietilä8Joey Lau9Maria H. Ulvmar10Mikael C. I. Karlsson11Maria Zetterling12Sara M. Mangsbo13Asgeir S. Jakola14Thomas Olsson Bontell15Anja Smits16Magnus Essand17Anna Dimberg18Department of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala UniversityDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala UniversityDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala UniversityDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala UniversityDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala UniversityDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala UniversityDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala UniversityDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala UniversityDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala UniversityDepartment of Medical Cell Biology, Uppsala UniversityDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala UniversityDepartment of Microbiology, Tumor and Cell Biology, Karolinska InstitutetDepartment of Neuroscience, Neurology, Uppsala UniversityDepartment of Pharmaceutical Biosciences, Science for Life Laboratory, Uppsala UniversityDepartment of Neurosurgery, Sahlgrenska University HospitalDepartment of Physiology, Institute of Neuroscience and Physiology, Sahlgrenska Academy, University of GothenburgDepartment of Neuroscience, Neurology, Uppsala UniversityDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala UniversityDepartment of Immunology, Genetics and Pathology, Science for Life Laboratory, The Rudbeck Laboratory, Uppsala UniversityAgonistic CD40 antibodies (αCD40) have broad immunostimulatory properties, however their efficacy in glioma remains unclear. Here the authors show that αCD40 promotes the formation of tertiary lymphoid structures but does not improve survival and impairs the response to immune checkpoint blockade in murine glioma models.https://doi.org/10.1038/s41467-021-24347-7 |
| collection |
DOAJ |
| language |
English |
| format |
Article |
| sources |
DOAJ |
| author |
Luuk van Hooren Alessandra Vaccaro Mohanraj Ramachandran Konstantinos Vazaios Sylwia Libard Tiarne van de Walle Maria Georganaki Hua Huang Ilkka Pietilä Joey Lau Maria H. Ulvmar Mikael C. I. Karlsson Maria Zetterling Sara M. Mangsbo Asgeir S. Jakola Thomas Olsson Bontell Anja Smits Magnus Essand Anna Dimberg |
| spellingShingle |
Luuk van Hooren Alessandra Vaccaro Mohanraj Ramachandran Konstantinos Vazaios Sylwia Libard Tiarne van de Walle Maria Georganaki Hua Huang Ilkka Pietilä Joey Lau Maria H. Ulvmar Mikael C. I. Karlsson Maria Zetterling Sara M. Mangsbo Asgeir S. Jakola Thomas Olsson Bontell Anja Smits Magnus Essand Anna Dimberg Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma Nature Communications |
| author_facet |
Luuk van Hooren Alessandra Vaccaro Mohanraj Ramachandran Konstantinos Vazaios Sylwia Libard Tiarne van de Walle Maria Georganaki Hua Huang Ilkka Pietilä Joey Lau Maria H. Ulvmar Mikael C. I. Karlsson Maria Zetterling Sara M. Mangsbo Asgeir S. Jakola Thomas Olsson Bontell Anja Smits Magnus Essand Anna Dimberg |
| author_sort |
Luuk van Hooren |
| title |
Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma |
| title_short |
Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma |
| title_full |
Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma |
| title_fullStr |
Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma |
| title_full_unstemmed |
Agonistic CD40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma |
| title_sort |
agonistic cd40 therapy induces tertiary lymphoid structures but impairs responses to checkpoint blockade in glioma |
| publisher |
Nature Publishing Group |
| series |
Nature Communications |
| issn |
2041-1723 |
| publishDate |
2021-07-01 |
| description |
Agonistic CD40 antibodies (αCD40) have broad immunostimulatory properties, however their efficacy in glioma remains unclear. Here the authors show that αCD40 promotes the formation of tertiary lymphoid structures but does not improve survival and impairs the response to immune checkpoint blockade in murine glioma models. |
| url |
https://doi.org/10.1038/s41467-021-24347-7 |
| work_keys_str_mv |
AT luukvanhooren agonisticcd40therapyinducestertiarylymphoidstructuresbutimpairsresponsestocheckpointblockadeinglioma AT alessandravaccaro agonisticcd40therapyinducestertiarylymphoidstructuresbutimpairsresponsestocheckpointblockadeinglioma AT mohanrajramachandran agonisticcd40therapyinducestertiarylymphoidstructuresbutimpairsresponsestocheckpointblockadeinglioma AT konstantinosvazaios agonisticcd40therapyinducestertiarylymphoidstructuresbutimpairsresponsestocheckpointblockadeinglioma AT sylwialibard agonisticcd40therapyinducestertiarylymphoidstructuresbutimpairsresponsestocheckpointblockadeinglioma AT tiarnevandewalle agonisticcd40therapyinducestertiarylymphoidstructuresbutimpairsresponsestocheckpointblockadeinglioma AT mariageorganaki agonisticcd40therapyinducestertiarylymphoidstructuresbutimpairsresponsestocheckpointblockadeinglioma AT huahuang agonisticcd40therapyinducestertiarylymphoidstructuresbutimpairsresponsestocheckpointblockadeinglioma AT ilkkapietila agonisticcd40therapyinducestertiarylymphoidstructuresbutimpairsresponsestocheckpointblockadeinglioma AT joeylau agonisticcd40therapyinducestertiarylymphoidstructuresbutimpairsresponsestocheckpointblockadeinglioma AT mariahulvmar agonisticcd40therapyinducestertiarylymphoidstructuresbutimpairsresponsestocheckpointblockadeinglioma AT mikaelcikarlsson agonisticcd40therapyinducestertiarylymphoidstructuresbutimpairsresponsestocheckpointblockadeinglioma AT mariazetterling agonisticcd40therapyinducestertiarylymphoidstructuresbutimpairsresponsestocheckpointblockadeinglioma AT sarammangsbo agonisticcd40therapyinducestertiarylymphoidstructuresbutimpairsresponsestocheckpointblockadeinglioma AT asgeirsjakola agonisticcd40therapyinducestertiarylymphoidstructuresbutimpairsresponsestocheckpointblockadeinglioma AT thomasolssonbontell agonisticcd40therapyinducestertiarylymphoidstructuresbutimpairsresponsestocheckpointblockadeinglioma AT anjasmits agonisticcd40therapyinducestertiarylymphoidstructuresbutimpairsresponsestocheckpointblockadeinglioma AT magnusessand agonisticcd40therapyinducestertiarylymphoidstructuresbutimpairsresponsestocheckpointblockadeinglioma AT annadimberg agonisticcd40therapyinducestertiarylymphoidstructuresbutimpairsresponsestocheckpointblockadeinglioma |
| _version_ |
1721308704881508352 |